Allogene Therapeutics (NASDAQ:ALLO) Issues Quarterly Earnings Results, Beats Estimates By $0.08 EPS

Allogene Therapeutics (NASDAQ:ALLO) released its quarterly earnings data on Thursday. The company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.08, FiscalAI reports.

Here are the key takeaways from Allogene Therapeutics’ conference call:

• ALPHA3 interim MRD readout in April: A planned futility analysis on 24 patients (12 per arm) will report MRD clearance and high-level safety, with the company targeting a 25%–30% absolute delta that, if achieved, could shift large B‑cell lymphoma treatment into first‑line consolidation and broaden community access.
• ALLO‑329 RESOLUTION proof‑of‑concept in June 2026: Management expects translational and early clinical signals for their dual CD19/CD70 allogeneic CAR‑T using Dagger technology, which could enable meaningful persistence at a low (20M) or no‑lymphodepletion dose and support scalable outpatient autoimmune use.
• Extended cash runway into Q1 2028: Allogene ended 2025 with $258.3M of cash and equivalents, received $23.7M from escrow, has raised ~$20.7M via ATM year‑to‑date, and guided 2026 operating cash burn of ~ $150M (GAAP ~$210M), positioning the company to fund ALPHA3 and RESOLUTION catalysts.
• Data and statistical uncertainty around early analyses: The April futility readout will be top‑line MRD and high‑level safety on a small 24‑patient sample and management is not disclosing full powering/statistical assumptions, which creates interpretation risk and potential short‑term volatility pending larger, definitive outcomes.

Allogene Therapeutics Stock Performance

Shares of Allogene Therapeutics stock traded down $0.09 during trading on Friday, hitting $2.39. 1,844,303 shares of the stock were exchanged, compared to its average volume of 5,633,140. Allogene Therapeutics has a 12 month low of $0.86 and a 12 month high of $2.80. The stock’s fifty day moving average is $1.92 and its 200 day moving average is $1.50. The stock has a market cap of $535.98 million, a PE ratio of -2.43 and a beta of 0.50.

Wall Street Analyst Weigh In

Several research analysts have recently commented on ALLO shares. Citizens Jmp raised shares of Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price target for the company in a report on Friday, January 9th. Wall Street Zen upgraded shares of Allogene Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, February 22nd. Citigroup upgraded Allogene Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Friday, January 9th. Finally, UBS Group initiated coverage on Allogene Therapeutics in a report on Wednesday, January 7th. They set a “buy” rating and a $8.00 target price for the company. Ten analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat, Allogene Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $8.40.

Insider Activity

In other news, EVP Zachary Roberts sold 35,700 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $1.77, for a total transaction of $63,189.00. Following the completion of the transaction, the executive vice president directly owned 581,166 shares in the company, valued at approximately $1,028,663.82. The trade was a 5.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Geoffrey M. Parker sold 24,001 shares of the stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $1.76, for a total value of $42,241.76. Following the completion of the transaction, the chief financial officer directly owned 1,252,795 shares of the company’s stock, valued at $2,204,919.20. This trade represents a 1.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 222,987 shares of company stock valued at $396,969. 13.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Allogene Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC acquired a new stake in shares of Allogene Therapeutics during the 1st quarter valued at $85,000. Goldman Sachs Group Inc. raised its position in shares of Allogene Therapeutics by 177.9% during the first quarter. Goldman Sachs Group Inc. now owns 5,853,974 shares of the company’s stock worth $8,547,000 after purchasing an additional 3,747,397 shares during the period. Jane Street Group LLC raised its position in shares of Allogene Therapeutics by 578.7% during the first quarter. Jane Street Group LLC now owns 1,116,681 shares of the company’s stock worth $1,630,000 after purchasing an additional 952,158 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Allogene Therapeutics by 13.0% during the second quarter. Geode Capital Management LLC now owns 3,794,827 shares of the company’s stock valued at $4,289,000 after purchasing an additional 435,389 shares during the last quarter. Finally, Rhumbline Advisers boosted its position in shares of Allogene Therapeutics by 14.0% in the 2nd quarter. Rhumbline Advisers now owns 209,336 shares of the company’s stock valued at $237,000 after purchasing an additional 25,628 shares during the period. 83.63% of the stock is currently owned by institutional investors and hedge funds.

About Allogene Therapeutics

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.

The company’s pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.